靶向 B7-H3 的 CAR-T 细胞颅内递送治疗复发性胶质母细胞瘤:1 期试验
Intracranial delivery of B7-H3-targeting CAR-T cells for recurrent glioblastoma: a phase 1 trial.
颅内 TX103 输注在 rGBM 中显示出可接受的安全性和令人鼓舞的疗效,支持未来在 RP2D(DL2,每次输注 6 10 7 个细胞)开展 2 期评估。
FRONTIER PAPERS
Intracranial delivery of B7-H3-targeting CAR-T cells for recurrent glioblastoma: a phase 1 trial.
颅内 TX103 输注在 rGBM 中显示出可接受的安全性和令人鼓舞的疗效,支持未来在 RP2D(DL2,每次输注 6 10 7 个细胞)开展 2 期评估。
Trained immunity in the treatment for haematological malignancy.
训练免疫作为一种新兴的治疗策略,通过调控固有免疫细胞的表观遗传和代谢重编程,赋予其长期抗肿瘤记忆,为血液系统恶性肿瘤的免疫治疗提供了新途径。
Total neoadjuvant chemotherapy combined with PD‑1 blockade and IL‑2 in MSS/pMMR locally advanced rectal cancer: short-term results of a prospective, s
共纳入33例患者,年龄18-75岁,直肠肿瘤位于距肛缘12 cm以内,分期为cT3/4N_anyM0或cT_anyN⁺M0。
CAR-T therapy moving to first-line in multiple myeloma: latest updates from the 2025 ASH annual meeting.
这些数据支持MM治疗模式的转变,即更早地整合CAR-T疗法。
HCCaging: a liver physiological aging-related biomarker for hepatocellular carcinoma diagnosis based on transcriptome data.
这些发现凸显了衰老在肝肿瘤发生中的双重作用。
AI-driven radiomics and radiogenomics: supporting the assessment and differentiation of pseudoprogression in cellular immunotherapy for glioblastoma.
胶质母细胞瘤(GBM)是成人中最具侵袭性的原发性脑肿瘤,治疗后也难以判断一个人的健康状况是否有所改善。
Venetoclax for elderly patients with acute myeloid leukaemia unfit for intensive chemotherapy: Prospects, resistance mechanisms and management strateg
然而,约30%的患者对基于venetoclax的联合方案无应答,且大多数初始应答者最终会复发。
In vivo generation of anti-BCMA CAR-T cells in relapsed or refractory multiple myeloma: a phase 1 study.
5例经多线治疗的男性患者(中位既往治疗线数为3线)被连续入组,并接受中位6.0个月的随访。
Therapeutic ecology of the fiber-microbiota-barrier axis in leukemia: resilience, immune recovery and pharmacomicrobiomics.
白血病诊疗是生态系统压力下的一项临床实验。
Awakening antitumour immunity in the multimorbid host: a hypothesis coupling cryoablation-induced immunogenic cell death with multi-target Traditional
大多数癌症患者是同时患有其他几种慢性疾病的老年人,而肿瘤及其最常见的伴随疾病——心血管代谢疾病、2型糖尿病和抑郁症——都由一个共同的免疫抑制性炎症环境所维持。
MEMBER ACCOUNT
登录成功会直接打开下一页。